Finally, to stratify the iCCA patients who might benefit from the use of MEK inhibitors, we assessed the mutations frequency in K-Ras as well as the activation of the MAPK signaling in a collection of human iCCA specimens. The gene discussed is KRAS; the disease is infantile convulsions and choreoathetosis.